search Created with Sketch.
search Created with Sketch.
search Created with Sketch.

Topics:

Acne

Cosmetic

Eczema

Infections

Pediatric

Practice Management

Psoriasis

Residents

Rosacea

Skin Cancer

Skin of Color

Search Results

Show Filters plus Created with Sketch.

Refine By Content Type plus Created with Sketch.

Refine By Year plus Created with Sketch.

Sort By:

Relevance Date

Relevance

Date

Oncology Watch Department Img
Oncology Watch | November 2019

Psoriasis and Cancer: Is There a Link?

New data adds to the evidence for a link between psoriasis and certain cancers, including skin cancer.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | June 2019

Sunscreen News, Views, and Miscues

What your patients—and you—should know about the latest developments around sunscreens.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | April 2019

An Update On Breast Implant-Associated Anaplastic Large Cell Lymphoma

The plastic surgery field is confronting renewed focus on risks for a rare cancer. Here’s an update.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | February 2019

Thin Melanomas: When is SLN Biopsy Indicated?

New research offers additional evidence that mitotic rate may have a role in clinical decision-making.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | December 2018

Melanoma Mortality: Women Maintain the Advantage

Global data show that men have higher rates of mortality and more rapid melanoma progression. We still don't know why.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | November 2018

Assessing Clinical Options for Moderately Dysplastic Nevi Excised with Positive Margins

The latest data support the decision to monitor patients rather than re-excise when the pathology report confirms moderate dysplasia with positive margins.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | October 2018

Update on Non-invasive Gene Expression Testing for Melanoma

A simple patch-style test may help support the need to biopsy suspicious lesions.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | September 2018

Statins and Skin Cancer: The Latest Data

A look at another commonly used drug and its potential association with skin cancer risks.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | July 2018

Exploring Hydrochlorothiazide Use and Skin Cancer Risk

A commonly used antihypertensive appears to be linked to an increased risk of SCC. What should dermatologists do?

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | May 2018

Pre-Treating Resectable Melanomas with PD-1 Inhibitors: An Emerging Strategy

Pre-treatment with anti-PD1 agents may improve outcomes for some patients and provide prognostic clues.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | April 2018

Who Needs UV Education and Who Should Provide It?

New recommendations from the United States Preventive Services Task Force seem to limit the PCP's role in patient UV education.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | February 2018

New NMSC Guidelines Highlight Options and Need for More Research

The latest guidelines of care for SCC and BCC endorse the standard of care and show we need additional, high-quality research into non-surgical options.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | September 2017

Total Body Skin Exams: Don't Abandon Them

Lesion-directed exams may save time, but is the limited temporal savings worth it?

Jonathan Wolfe, MD, FAAD

Oncology Watch Department Img
Oncology Watch | August 2017

The Clinical Significance of Gene Expression Profile Testing for Melanoma

Accumulated evidence on GEP Classification suggests that it provides clinically relevant information that can influence patient management for the better.

Jonathan Wolfe, MD, FAAD

Oncology Watch Department Img
Oncology Watch | June 2017

High-Dose Ipilimumab Shows Benefits in Advanced Melanoma: Implications for Care

Although treatment is associated with a high rate of toxicity, survival benefit is extended at a higher dose.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | May 2017

A Non-Invasive 2-Gene Molecular Assay Shows Promise in Assessment of Pigmented Lesions

More studies are needed, but a non-invasive assay that identified melanoma gene expression could support clinical decision making.

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | March 2017

Sunscreen Perceptions, Promotion, and Use: Dermatologists' Perspectives

What do dermatologists really think about the benefits of sunscreen?

Jonathan Wolfe, MD

Oncology Watch Department Img
Oncology Watch | January 2017

Invasive Melanoma: Incidence, Mortality Continue to Climb

The burden of disease is growing, despite best efforts to combat melanoma.

Jonathan Wolfe, MD, Section Editor

Oncology Watch Department Img
Oncology Watch | December 2016

Risk Factor: Characterizing Melanoma Risk Clinically

Can clinical features help determine an individual's melanoma risk?

Jonathan Wolfe, MD, Section Editor

Oncology Watch Department Img
Oncology Watch | November 2016

The “Aged Microenvironment”: New Understandings of Melanoma Spread and Aggression

New research sheds light on pathways through which melanoma may become more aggressive.

Jonathan Wolfe, MD

VIEW MORE